DNL593 — Interim data
2026
Phase 2 Part B interim data in patients with FTD-GRN will read out in 2026Source filing
DNLI biotech catalysts & pipeline
DENALI THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
TAK-594/DNL593 (PTV:PGRN) — Initial data
2026
Initial FTD- GRN patient data are expected in 2026.Source filing
DNL151 (LRRK2 inhibitor) — Topline data
H1 2027
Data from BEACON are expected in the first half of 2027.Source filing
DNL593 — Topline data
in 2027
Denali now expects results from the study in 2027, updated from its prior expectation of results by the end of 2026.Source filing
DNL628 — Topline data
1H 2027
Denali expects data from this study in 1H 2027.Source filing
DNL921 — Topline data
in 2027
Safety and clinical proof-of-concept data from the ongoing Phase 1/1b study of DNL921 in healthy volunteers and participants with Alzheimer's disease are expected in 2027.Source filing
DNL952 — Initial data
in 2027
Dosing of participants with late-onset Pompe disease began in the Phase 1 study of DNL952 in the second quarter of 2026, and initial clinical data are expected in 2027.Source filing
zafinofusp alfa (DNL126; ETV:SGSH) — NDA/BLA submission
in 2027
Denali expects a Biologics License Application (BLA) submission and potential accelerated approval for zafinofusp alfa for Sanfilippo syndrome type A in 2027.Source filing